Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared an article on X:
“Still in ASCO 2026 we are seeing trials, particularly for IO combinations that significantly exclude women.
OptiTrop-Lung 05: Sac-TMT + Pembro vs Pembro alone in 1L NSCLC.
24% were women and in the PD-L1 TPS ≥50% subgroup, 17% were women.”
Other articles about ASCO on OncoDaily.
